Lucid Diagnostics Inc. (LUCD) NASDAQ
1.03
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.03
+0(+0.00%)
Currency In USD
Address
One Grand Central Place
New York City, NY 10165
United States of America (the)
Phone
212 949 4319
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
72
First IPO Date
October 14, 2021
| Name | Title | Pay | Year Born |
| Lishan Aklog | Chairman & Chief Executive Officer | 450,000 | 1966 |
| Helen Moinova | Co-founder & Strategic Advisor | 14,535 | N/A |
| Amitabh Chak | Co-founder & Strategic Advisor | 14,535 | N/A |
| Sanford D. Markowitz | Co-founder & Strategic Advisor | 14,535 | N/A |
| Joseph Willis | Co-founder & Strategic Advisor | 14,535 | N/A |
| Dennis McGrath | Chief Financial Officer | 303,750 | 1957 |
| Michael Adam Gordon | General Counsel & Secretary | 312,500 | 1975 |
| Shaun O'Neill | President & Chief Operating Officer | 375,000 | 1982 |
| Deepika A. Lakhani | Senior Vice President, Chief Regulatory & Quality Officer | 0 | N/A |
| Suman Verma | Senior VP & Chief Scientific Officer | 0 | N/A |
| Matthew Riley | Director of Investor Relations | 0 | N/A |
| Danielle W. Scelfo | Senior Vice President of Market Access & Government Affairs | 0 | N/A |
| Brian J. deGuzman | Chief Technology & Compliance Officer | 0 | 1965 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.